Genotropin — Revenues:
Pfizer Genotropin — Revenues: decreased by 20.5% to $93.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 2.1%, from $95.00M to $93.00M. Over 4 years (FY 2021 to FY 2025), Genotropin — Revenues: shows an upward trend with a 3.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests sustained market demand or successful pricing strategies for the therapy, while a decrease may indicate increased competition from biosimilars or a shift in clinical treatment standards.
Detailed definition
This metric represents the total net sales generated from the Genotropin product line, which is a recombinant human grow...
Peer comparison
Comparable to revenue metrics for specific mature specialty drugs or legacy therapeutic franchises at other large-cap pharmaceutical companies.
pfe_segment_genotropin_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $109.00M | $95.00M | $105.00M | $80.00M | $91.00M | $90.00M | $99.00M | $147.00M | $74.00M | $158.00M | $160.00M | $120.00M | $119.00M | $119.00M | $112.00M | $95.00M | $106.00M | $128.00M | $117.00M | $93.00M |
| QoQ Change | — | -12.8% | +10.5% | -23.8% | +13.8% | -1.1% | +10.0% | +48.5% | -49.7% | +113.5% | +1.3% | -25.0% | -0.8% | +0.0% | -5.9% | -15.2% | +11.6% | +20.8% | -8.6% | -20.5% |
| YoY Change | — | — | — | — | -16.5% | -5.3% | -5.7% | +83.8% | -18.7% | +75.6% | +61.6% | -18.4% | +60.8% | -24.7% | -30.0% | -20.8% | -10.9% | +7.6% | +4.5% | -2.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Pfizer's genotropin — revenues:?
- Pfizer (PFE) reported genotropin — revenues: of $93.00M in Q1 2026.
- How has Pfizer's genotropin — revenues: changed year-over-year?
- Pfizer's genotropin — revenues: decreased by 2.1% year-over-year, from $95.00M to $93.00M.
- What is the long-term trend for Pfizer's genotropin — revenues:?
- Over 4 years (2021 to 2025), Pfizer's genotropin — revenues: has grown at a 3.5% compound annual growth rate (CAGR), from $389.00M to $446.00M.
- What does genotropin — revenues: mean?
- The total revenue generated from sales of the Genotropin growth hormone product.